Edwards Lifesciences (EW) to Release Quarterly Earnings on Wednesday

Edwards Lifesciences (NYSE:EW - Get Free Report) is expected to be posting its quarterly earnings results after the market closes on Wednesday, April 23rd. Analysts expect the company to announce earnings of $0.60 per share and revenue of $1.40 billion for the quarter. Edwards Lifesciences has set its FY 2025 guidance at 2.400-2.500 EPS and its Q1 2025 guidance at 0.580-0.640 EPS.Parties interested in registering for the company's conference call can do so using this link.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, analysts expect Edwards Lifesciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Price Performance

NYSE:EW traded up $0.36 during trading hours on Friday, reaching $71.56. The stock had a trading volume of 3,235,636 shares, compared to its average volume of 4,927,071. The stock has a market capitalization of $42.07 billion, a PE ratio of 10.27, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a 50 day moving average price of $71.31 and a two-hundred day moving average price of $70.85.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 6,500 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the sale, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,555,402. The trade was a 12.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven R. Loranger sold 5,739 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,853 shares of company stock valued at $5,163,062 in the last quarter. Company insiders own 1.29% of the company's stock.

Institutional Trading of Edwards Lifesciences

An institutional investor recently bought a new position in Edwards Lifesciences stock. Brighton Jones LLC acquired a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,587 shares of the medical research company's stock, valued at approximately $266,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research reports. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Morgan Stanley increased their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Piper Sandler raised their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Barclays increased their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Finally, Truist Financial cut their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of "Hold" and a consensus target price of $78.55.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.